JPET Celsis microsomes equal better data

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Yu, J.-C.
Right arrow Articles by Giese, N. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yu, J.-C.
Right arrow Articles by Giese, N. A.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH

Vol. 298, Issue 3, 1172-1178, September 2001

Efficacy of the Novel Selective Platelet-Derived Growth Factor Receptor Antagonist CT52923 on Cellular Proliferation, Migration, and Suppression of Neointima following Vascular Injury

Jin-Chen Yu, Nathalie A. Lokker, Stanley Hollenbach, Mutiah Apatira, Jason Li, Andreas Betz, David Sedlock, Shoji Oda, Yuji Nomoto, Kenji Matsuno, Shin-ichi Ide, Eiji Tsukuda and Neill A. Giese

COR Therapeutics, Inc., South San Francisco, California (J.-C.Y., N.L., S.H., M.A., J.L., A.B., D.S., N.A.G.); and Kyowa Hakko Kogyo Co., Ltd., Pharmaceutical Research Institute, Shizuoka, Japan (S.O., Y.N., K.M., S.-i.I., E.J.)

Exaggerated or inappropriate signaling by the platelet-derived growth factor receptor (PDGFR) tyrosine kinase has been implicated in a wide variety of diseases. Thus, a series of piperazinyl quinazoline compounds were identified as potent antagonists of the PDGFR by screening chemical libraries. An optimized analog, CT52923, was shown to be an ATP-competitive inhibitor that exhibited remarkable specificity when tested against other kinases, including all members of the closely related PDGFR family. The PDGFRs and stem cell factor receptor were inhibited with an IC50 of 100 to 200 nM, while 45- to >200-fold higher concentrations of CT52923 were required to inhibit fms-like tyrosine kinase-3 and colony-stimulating factor-1 receptor, respectively. Other receptor tyrosine kinases, cytoplasmic tyrosine kinases, serine/threonine kinases, or members of the mitogen-activated protein kinase pathway were not significantly inhibited at 100- to 1000-fold higher concentrations. In addition, this compound also demonstrated specificity for inhibition of cellular responses. Platelet-derived growth factor-induced smooth muscle cell migration or fibroblast proliferation was found to be blocked by CT52923 with an IC50 of 64 and 280 nM, respectively, whereas 50- to 100-fold higher concentrations were required to inhibit these responses when induced with fibroblast growth factor. To investigate the effect of CT52923 on PDGFR signaling, in vivo studies demonstrated that CT52923 could significantly inhibit neointima formation following carotid artery injury by oral administration in the rat. Therefore, PDGFR antagonism by CT52923 could be a viable strategy for the prevention of clinical restenosis or the treatment of other human diseases involving PDGFR signaling.

0022-3565/01/2983-1172$03.00/0
THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Copyright © 2001 by The American Society for Pharmacology and Experimental Therapeutics


This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
K. T. Flaherty
Sorafenib in Renal Cell Carcinoma
Clin. Cancer Res., January 15, 2007; 13(2): 747s - 752s.
[Abstract] [Full Text] [PDF]

Home page
 Mayo Clin. Proc.Home page
R. H. Alvarez, H. M. Kantarjian, and J. E. Cortes
Biology of Platelet-Derived Growth Factor and Its Involvement in Disease
Mayo Clin. Proc., September 1, 2006; 81(9): 1241 - 1257.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
S. L. Warner, S. Bashyam, H. Vankayalapati, D. J. Bearss, H. Han, D. D. Von Hoff, and L. H. Hurley
Identification of a lead small-molecule inhibitor of the Aurora kinases using a structure-assisted, fragment-based approach.
Mol. Cancer Ther., July 1, 2006; 5(7): 1764 - 1773.
[Abstract] [Full Text] [PDF]

Home page
 Stem CellsHome page
B. W. Parcells, A. K. Ikeda, T. Simms-Waldrip, T. B. Moore, and K. M. Sakamoto
FMS-Like Tyrosine Kinase 3 in Normal Hematopoiesis and Acute Myeloid Leukemia
Stem Cells, May 1, 2006; 24(5): 1174 - 1184.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
D. Ma, C. L. Nutt, P. Shanehsaz, X. Peng, D. N. Louis, and D. M. Kaetzel
Autocrine Platelet-Derived Growth Factor-Dependent Gene Expression in Glioblastoma Cells Is Mediated Largely by Activation of the Transcription Factor Sterol Regulatory Element Binding Protein and Is Associated with Altered Genotype and Patient Survival in Human Brain Tumors
Cancer Res., July 1, 2005; 65(13): 5523 - 5534.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
W. G. Roberts, P. M. Whalen, E. Soderstrom, G. Moraski, J. P. Lyssikatos, H.-F. Wang, B. Cooper, D. A. Baker, D. Savage, D. Dalvie, et al.
Antiangiogenic and Antitumor Activity of a Selective PDGFR Tyrosine Kinase Inhibitor, CP-673,451
Cancer Res., February 1, 2005; 65(3): 957 - 966.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
A. Ertmer, S. Gilch, S.-W. Yun, E. Flechsig, B. Klebl, M. Stein-Gerlach, M. A. Klein, and H. M. Schatzl
The Tyrosine Kinase Inhibitor STI571 Induces Cellular Clearance of PrPSc in Prion-infected Cells
J. Biol. Chem., October 1, 2004; 279(40): 41918 - 41927.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
K. Kozaki, W. E. Kaminski, J. Tang, S. Hollenbach, P. Lindahl, C. Sullivan, J.-C. Yu, K. Abe, P. J. Martin, R. Ross, et al.
Blockade of Platelet-Derived Growth Factor or Its Receptors Transiently Delays but Does Not Prevent Fibrous Cap Formation in ApoE Null Mice
Am. J. Pathol., October 1, 2002; 161(4): 1395 - 1407.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
N. A. Lokker, C. M. Sullivan, S. J. Hollenbach, M. A. Israel, and N. A. Giese
Platelet-derived Growth Factor (PDGF) Autocrine Signaling Regulates Survival and Mitogenic Pathways in Glioblastoma Cells: Evidence That the Novel PDGF-C and PDGF-D Ligands May Play a Role in the Development of Brain Tumors
Cancer Res., July 1, 2002; 62(13): 3729 - 3735.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 2001 by the American Society for Pharmacology and Experimental Therapeutics.